Speaker illustration

Doctor Essra Ridha

Bristol-Myers Squibb Pharmaceuticals Limited , London (United Kingdom of Great Britain & Northern Ireland)

Are your atrial fibrillation (AF) patients protected from ischaemic stroke? Clinical characteristics of AF patients eligible for stroke prevention but remaining untreated in UK clinical practice

Event: ESC CONGRESS 2016

Topic: Atrial fibrillation (AF)

Session: Anticoagulation in atrial fibrillation II

Thumbnail

Is Aspirin monotherapy effective for stroke prevention in the real world? A UK cohort study evaluating the incidence of stroke in the absence of anticoagulation in atrial fibrillation (AF)

Event: ESC CONGRESS 2016

Topic: Atrial fibrillation (AF)

Session: Anticoagulation in atrial fibrillation II

Thumbnail

Aspirin, not without bleeding risk in the real world: results of a UK cohort study evaluating the use of antiplatelet therapy for stroke prevention in atrial fibrillation (AF)

Event: ESC CONGRESS 2016

Topic: Atrial fibrillation (AF)

Session: Anticoagulation in atrial fibrillation III

Thumbnail

This platform is supported by

logo Novo Nordisk